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Objective: The Artificial Valve Endocarditis Reduction Trial was stopped on January 21, 2000, due to a higher
incidence of paraprosthetic leak in the St Jude Medical Silzone prosthesis compared with the conventional pros-
thesis. The Artificial Valve Endocarditis Reduction Trial investigators reported the 2-year results in 2002. This
retrospective study assessed the influence on thromboembolism and paraprosthetic leak to 7 years.
Methods: A total of 253 patients had 254 operations: 80 aortic valve replacements, 139 mitral valve replace-
ments, and 35 multiple replacements with placement of Silzone prostheses. The mean age was 58.6 years (range
21–84 years, median age 59.8 years), and there were 126 women (49.8%) and 74 concomitant procedures
(coronary artery bypass 28.9%).
Results:Major paraprosthetic leak (repair, re-replacement, or mortality) occurred in 10 of the original procedures
after 30 days (3 aortic valve replacements, 3 mitral valve replacements, 4 multiple replacements). Nine occur-
rences in 8 patients—5 early (2 years) and 4 late (>2 years)—were managed. Seven were managed with defin-
itive re-replacement. One was an early nonoperative fatality. There was 1 late fatality after the second late
paraprosthetic leak reoperation. One of the 10 procedures occurring after 2 years had mild to moderate aortic
valve replacement paraprosthetic leak managed as an incidental re-replacement at the time of correction of supra
valvular patch stenosis. One additional occurrence, in addition to the 8 patients (<30 days), was considered a tech-
nical error and not related to the Silzone prosthesis and was replaced with a Silzone prosthesis. The linearized rate
of paraprosthetic leak within the first 2 years of follow-up was 1.3%/patient-year and after 2 years was 0.4%/
patient-year. The linearized occurrence rate for major thromboembolism was 0.42%/patient-year for aortic valve
replacement and 1.71%/patient-year for mitral valve replacement.
Conclusions: Paraprosthetic leak with the St Jude Medical Silzone prosthesis was managed both during the early
(2 years) and late (>2years) intervals with re-replacement. Late managed events may be manifestations of ear-
lier occurring paraprosthetic leak. Follow-up echocardiograms should meet standards of care, 6 to 12 months after
surgery and at the slightest suspicion of dysfunction. There is no advanced continuing risk of the St Jude Medical
Silzone prosthesis.Supplemental material is available online.
Prosthetic valve endocarditis is an infrequent but severe
complication following heart valve replacement. St Jude
Medical introduced Silzone, silver impregnated onto the
sewing cuff of all valvular products as prophylaxis against
early prosthetic valve endocarditis, in 1998. The Artificial
Valve Endocarditis Reduction Trial (AVERT) was com-
menced in July of 1998 and was suspended on January 21,
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a higher incidence of paraprosthetic leak (PPL) in the Sil-
zone arm of the trial. The trial had placed implants in 807
of the anticipated 4400 patients. Worldwide, 36,000 implan-
tations were performed before the study was suspended, and
the valve was voluntarily removed from the market by St
Jude Medical. This center, participating in AVERT, ran-
domized 90 patients (44 Silzone). Our center placed 254 im-
plants in 253 patients, inclusive of the 44 patients enrolled in
AVERT. The purpose of the study was to assess the influ-
ence of the St Jude Medical Silzone on late thromboembo-
lism and PPL and to provide surveillance recommendations.
The investigators of the AVERT trial in Europe and North
America reported the results of this multicenter, interna-
tional, prospective, randomized trial in 2002.1 Major PPL
(followed by repair, explant, or mortality) occurred in 18
of 403 patients (4.5%) with Silzone prostheses and 4 of
404 patients (1.0%) with conventional prostheses. The 2-
year event-free rates were 91.1% for Silzone versus
98.9% for conventional prostheses (P ¼ .0025). Similarly,
the 2-year freedom from explant was 90.1% and 99.4%,
respectively, for Silzone and conventional prosthesesrdiovascular Surgery c Volume 137, Number 5 1109




AVERT ¼ Artificial Valve Endocarditis
Reduction Trial
AVR ¼ aortic valve replacement
MR ¼ multiple replacements
MVR ¼ mitral valve replacement
OPC ¼ Objective Performance Criteria
PPL ¼ paraprosthetic leak
(P ¼ .0002). The freedom from thromboembolism was not
different: 91.2% for Silzone and 93.4% for conventional
prostheses (P ¼ .32).
MATERIAL AND METHODS
Patients
The St Jude Medical Silzone valvular prosthesis was implanted in 253
patients (254 procedures; mean patient age 58.6 years, range 21–84 years,
median 59.8 years) between 1998 and January 2000, when the prosthesis
was voluntarily withdrawn from the worldwide market with suspension of
the AVERT trial. There were 127 men (50.2%) and 126 women (49.8%)
in the total cohort of 253 patients. There were 254 operations: 80
(31.5%) aortic valve replacements (AVRs); 139 (54.7%) mitral valve
replacements (MVRs); and 35 (13.8%) multiple replacements (MR). One
patient having MVR also had a second Silzone prosthesis implanted at
a second reoperation procedure for technical error and PPL. Concomitant
procedures were performed in 102 patients (40.2%), including 74 concom-
itant coronary artery bypass procedures (28.9%).
The total cumulative follow-up was 1399.7 years with a mean follow-up
of 5.5  2.3 years (median 6.3 years). The follow-up had a closing interval
of 2 months in November 2005.
Study Definitions
The study was conducted under the standard definitions of The Society
of Thoracic Surgeons/American Association for Thoracic Surgery/Euro-
pean Association for Cardio-thoracic Surgery ‘‘Guidelines for Reporting
Morbidity and Mortality after Cardiac Valvular Operations.’’2 Major PPL
was defined (as in the AVERT publications) as a paravalvular leak that
led to prosthesis repair, prosthesis explant, or mortality.
Thromboembolism events included major cerebrovascular accidents,
transient ischemic attacks, reversible ischemic neurologic deficits, arterial
embolization, and embolic myocardial infarction. Valve thrombosis was de-
fined as thrombus attached to or near the study valve, occluding blood flow
or interfering with function (proven by operation, autopsy, or clinical inves-
tigation), exclusive of infection. Hemorrhage was defined as bleeding result-
ing in blood transfusion and/or hospitalization.
Statistical Methods
The early and late complications were analyzed with conventional
techniques. The 30-day event complications and mortality rates were pre-
sented as crude rates without time involved. Linearized rates (%/patient-
year) for events beyond 30 days were calculated by taking the total
number of late events divided by the sum of the late follow-up years
beyond 30 days. The Kaplan-Meier event-free analysis method was
used to calculate freedom from various valve-related complications. The
Kaplan-Meier analysis included both early and late events but only the
first of each type for each patient. Comparisons were performed with
the log-rank test.1110 The Journal of Thoracic and Cardiovascular SuRESULTS
The actuarial analyses of the results for the overall popu-
lation and the separate populations of AVR, MVR, and MR
are presented in graphic form in Figures 1 and 2 and the sup-
plemental electronic Figures E1 to E9, stated at the intervals
of 5 and 7 years.
The overall patient survival depicting all-cause mortality
is illustrated in Figure 1. The overall survival at 7 years
was 80.3%  2.7%, for AVR 85.5%  4.4%, and for
MVR 79.8%  3.7%.
The early and late predominant valve-related complica-
tions are detailed in Table 1 and are presented as crude 30-
day event rates and late linearized occurrence rates (plus
95% confidence intervals). There were 4 early major throm-
boembolic events: 1 AVR and 3 MVRs. There were 6 early
hemorrhagic events: 2 AVRs, 2 MVRs, and 2 MR. There
was 1 fatal MVR hemorrhagic event. There was 1 early
MVR PPL, which resulted in 2 reoperations in less than 3
weeks and was classified as technical failure.
FIGURE 1. All-cause mortality overall and for aortic valve replacement
(AVR), mitral valve replacement (MVR), and multiple replacements (MR).
FIGURE 2. Major paraprosthetic leak (reoperation and fatal) overall and
for aortic valve replacement (AVR), mitral valve replacement (MVR), and
multiple replacements (MR).rgery c May 2009
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DTABLE 1. Early events and late linearized rates (%/patient-year) for AVR, MVR, and MR complications
AVR MVR MR
Early Late CI Early Late CI Early Late CI
TE MajorþRIND 1 0.42 (2) 0.00–1.00 3 1.71 (13) 0.79–2.64 0 0 (0) —
Hemorrhage 2 1.67 (8) 0.52–2.82 2* 1.98 (15) 0.99–2.97 2 4.28 (7*) 1.18–7.38
Major PVL 0 0.63 (3*) 0.00–1.34 1 0.40 (3) 0.00–0.84 0 2.45 (4*) 0.08–4.81
VR REOP 0 0.63 (3y) 0.00–1.34 2 0.53 (4z) 0.01–1.04 0 3.06 (5y) 0.42–5.70
PVE 0 0.21 (1) 0.00–0.62 2 0.00 (0) 0.00–0.00 0 0.61 (1) 0.00–0.81
Thrombosis 0 0.00 (0) 0.00–0.00 0 0.13 (1) 0.00–0.39 0 0.00 (0) 0.00–0.00
AVR, Aortic valve replacement; CI, confidence interval; MR, multiple replacements; MVR, mitral valve replacement; PVE, prosthetic valve endocarditis; PVL, paravalvular leak;
RIND, reversible ischemic neurologic deficits; TE, thromboembolism; VR REOP, valve-related reoperation. *Fatal (1). yPVE (1). zThrombosis (1).The late event rates for major thromboembolism for
AVR were 0.42%/patient-year (2 events) and for MVR,
1.71%/patient-year (13 events; Table 1).Therewereno events
in the multiple valve cohort. The hemorrhage rates ranged
from 1.67%/patient-year (8 events) for AVR to 1.98%/
patient-year (15 events) for MVR and to 4.31%/patient-year
(7 events) for MR. There was 1 late MR hemorrhagic fatality.
The major late PPL event rates were 0.63/patient-year (3
events) for AVR, 0.40%/patient-year (3 events) for MVR,
and 2.45%/patient-year (4 events) for MR (Tables 1, 2,
and 3). There was 1 AVR PPL fatality; this patient was de-
finitively diagnosed 15 months postoperatively and died the
same month under consideration for reoperation (Table 3).
One patient with MR had a sixth valvular operation in 24
years; the fifth was a repair of PPL of an aortic Silzone pros-
thesis and the sixth was a further aortic valved conduit oper-
ation for an additional PPL at a remote surgical position. The
patient subsequently died.
The late linearized rate for events within 2 years of sur-
gery for major PPL was 1.3%/patient-year, and the lateThe Journal of Thoracic and Cevent rate during the subsequent follow-up period was
0.4%/patient-year.
The reoperation rates were 0.63%/patient-year (3 events)
for AVR, 0.53%/patient-year (4 events) for MVR, and
3.06%/patient-year (5 events) forMR (Table 1). These reop-
erations were all for PPL except for an aortic and multiple
prosthetic valve endocarditis and a thrombosed mitral pros-
thesis (Table 3).
The details of the PPL occurrences are summarized in
Tables 2 and 3. Five of the 9 PPLs were diagnosed at 2
years for surgical management. Of the 4 PPLs diagnosed
at>2 years, 1 patient with AVR had re-replacement surgery
at 6.3 years and 1 multiple replacement-AVR repair at 4.7
years, and subsequently was replaced with a mechanical
valve conduit at 5.7 years and another MR-MVR with re-
placement surgery at 5.8 years with aortic valve and mitral
valve bioprostheses. The additional AVR occurrence had in-
cidental re-replacement for mild to moderate PPL at surgery
for revision of an aortic annular enlarging patch causing
supravalvular stenosis (Table 3). MR reoperation at 4.7TABLE 2. Summary of location, timing, and details of reoperation for PPLs considered related to Silzone prosthesis (including 6 major and 1 mild
to moderate leak)
Location Timing Details
AVR 5.1 y Mild to moderate PPL and supravalvular stenosis (serial mean gradients up to 40 mm Hg) from previous aortic
root annular enlarging patch. Re-replacement and patch revision.
AVR 6.3 y Ascending aortic aneurysm resection prior to Silzone AVR. Congestive heart failure at 5.7 y, PPL confirmed
and re-replacement at 6.3 y.
MVR 5.5 mo Major PPL, not considered of infective etiology. Re-replacement.
MVR 5.3 mo Reoperation for thrombosed conventional prosthesis with Silzone prosthesis followed at 5 mo for major PPL
with attempted repair/re-replacement.
MR (AVR) 4.7 y Six valvular operations in 24 years. Initial Starr-Edwards AVR (Edwards Lifesciences, Irvine, Calif), Medtronic
Intact (Medtronic, Inc, Minneapolis, Minn) porcine for mechanical structural valve deterioration, further
Medtronic Intact porcine for prosthetic valve endocarditis. Nine years later, AVR and MVR Silzone for
suspected endocarditis. At 4.7 y, moderate PPL, noncoronary leaflet PPL repaired. One year later, composite
mechanical root replacement for major PPL at different annular site, just left of the native right coronary
ostia; patient subsequently died in hospital.
MR (MVR) 7.5 mo Initially AVR andMVRCarboMedics mechanical prostheses (Sorin-CarboMedics, Austin, Tex); at 4.3 yMVR
thrombosed and replaced with MVR Silzone. Reoperation at 7.5 mo for major MVR PPL, re-replacement.
MR (MVR) 5.8 y Initially mitral commissurotomy, 21 y later AVR and MVR mechanical prostheses, then 11 y later AVR
incidental and MVR for PPL, both replaced with Silzone prostheses. Diagnosed with PPL both prostheses
and hemolytic anemia. Re-replacement with bioprostheses for mild AVR PPL and major MVR PPL.
AVR, Aortic valve replacement; MR, multiple replacements; MVR, mitral valve replacement; PPL, paraprosthetic leak.ardiovascular Surgery c Volume 137, Number 5 1111
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Dyears revealed a PPL in the area of noncoronary leaflet at the
repair reoperation and at 5.7 years to the left of the right cor-
onary ostia of the right coronary leaflet at the second reoper-
ation (Table 2).
The 4 earlier-diagnosed major PPLs (3 managed with re-
replacement, and 1 nonoperative death) were evident be-
tween 5 and 15 months. The timing of occurrence of the 5
later major PPLs is uncertain, as these leaks may have be-
come progressively larger over time. The documentation
of all major PPL reoperations was reviewed to determine ex-
tenuating circumstances but none were identified including
annulus considerations, inclusive of residual calcification.
The freedom at 7 years from each of the valve-related com-
plications is illustrated in Table 4, Figure 2, and Figures E1 to
E9. The freedom from major PPL (by definition, reoperation
plus nonoperative fatality) at 7 years was 95.2% 1.5% for
the overall population (Figure 2), 94.9%  2.9% for AVR,
and 97.7%  1.3% for MVR. The 10 major PPLs are de-
tailed, as documented above, in Tables 1, 2, and 3.
There were also a total of 8 minor PPL events (0.57%/
patient-year) that did not require reoperation and were
identified on routine echocardiographic examinations. These
minor PPL events were 0.42/patient-year (2 events) for
TABLE 3. Summary of location, timing, and details of PPLs
Location Timing Details
Major PPL: nonoperative mortality
AVR 15 mo Mild to moderate PPL,
progressed to major by 14 mo;
following definitive diagnosis,
patient died at 15 mo, under
consideration for reoperation.
Early PPL considered non-Silzone-related technical error
MVR 8 d Two reoperations early within
19 d for major PPL; considered
etiology was technical error.
AVR, Aortic valve replacement; MVR, mitral valve replacement; PPL, paraprosthetic
leak.1112 The Journal of Thoracic and Cardiovascular SAVR, 0.13%/patient-year (1 event) for MVR, and 3.0%/
patient-year (5 events) for MR.
DISCUSSION
In 1997 and 1998, St Jude Medical received regulatory
approval to impregnate the sewing cuffs of valvular
prostheses with permanent metallic silver, named ‘‘Silzone’’
coating, to act as prophylaxis against prosthetic valve endo-
carditis, both an early and late valve-related complication.
Subsequently, all St Jude Medical products were impreg-
nated with metallic silver. In 1998, the AVERT was com-
menced with the anticipation of randomizing 4400 patients
in North America and Europe.3 The Data Safety Monitoring
Board stopped the trial on January 21, 2000, with 807 pa-
tients enrolled, because of an increased incidence of major
PPL in the Silzone arm compared with the conventional
cuff arm. St Jude Medical voluntarily withdrew Silzone
products from the worldwide market.
The affiliated teaching hospitals, Vancouver General Hos-
pital and St Paul’s Hospital, of the University of British Co-
lumbia, had contributed 90 of the institutions’ expected 100
patients to the trial. This institutional review of 253 patients
incorporates the 44 Silzone patients randomized in AVERT.
This review was conducted to contribute to evidence of any
continuing risk of late major PPLs necessitating reoperation
and major thromboembolic risk of residual morbidity.
The estimated number of patients still alive is approxi-
mately 24,000 worldwide of the original 36,000. This report
also attempted to evaluate current evidence for surveillance
of this large patient population.
The 2-year results of AVERT were published by Schaff
and the AVERT investigators in 2002.1 The summary of
the 2002 results are outlined in the introduction of this article
and in Table 5. The number of major PPLs requiring explant
reoperation remained statistically different at 2 years, al-
though the major thromboembolic rate remained undifferen-
tiated statistically. Prior to the 2002 AVERT report, thereTABLE 4. Summary of actuarial analyses (freedom at 7 years; presentation of analyses in electronic Figures E1–E9)
Figure Overall AVR MVR MR
E1: valve-related reoperation 95.1  1.5 95.0  2.9 97.6  1.4 84.2  7.3
E2: PPL reoperation 96.4  1.4 96.2  2.7 98.4  1.1 87.7  6.7
E3: PPL reoperation mortality 99.5  0.5 — — —
E4: overall thromboembolism, minor TE, RIND, major TE with/
without thrombosisþmajor systemic embolism
With: 78.2  3.1
Without: 78.5  3.1
— — —
E5: combined RIND and major TE with thrombosisþmajor
systemic embolism
90.3  2.2 94.9  3.0 85.0  3.7 100
E6: combined RIND and major TE without thrombosisþmajor
systemic embolism
90.7  2.2 94.9  3.0 85.8  3.6 100
E7: thrombosis 99.5  0.4 — 99.2  0.8 —
E8: antithrombotic hemorrhage 84.8  2.7 89.1  3.6 85.6  3.7 69.1  10.5
E9: prosthetic valve endocarditis 98.3  0.8 98.7  1.3 98.5  1.0 96.0  3.9
AVR, Aortic valve replacement; MR, multiple replacements; MVR, mitral valve replacement; PPL, paraprosthetic leak; RIND, reversible ischemic neurologic deficits; TE,
thromboembolism.urgery c May 2009
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DTABLE 5. Summary of reported late event rates (2002 and 2005) and optimal performance criteria for valve replacement devices of the Food and
Drug Administration
No Silzone,%/patient-year (95% CI) Silzone,%/patient-year (95% CI)
2002 2005 2002 2005 OPC
Major prosthetic valve leak 0.6%/y
Aortic 0.9 (0.2–3.0) 0.4 (0.1–0.9) 3.5 (1.7–6.7) 0.6 (0.3–1.2)
Mitral 1.5 (0.3–4.9) 0.3 (0.1–1.1) 7.0 (3.1–13.8) 1.6 (0.7–2.9)
Any prosthetic valve leak 1.2%/y
Aortic 2.3 (0.9–5.1) 0.7 (0.3–1.3) 5.3 (2.9–9.0) 1.3 (0.7–2.1)
Mitral 3.8 (1.5–8.4) 1.0 (0.4–2.0) 8.0 (3.8–15.1) 2.3 (1.3–4.0)
Thromboembolic events 3.0%/y
Aortic 1.4 (0.4–3.7) 1.6 (1.0–2.5) 2.6 (1.1–5.5) 1.5 (0.9–2.4)
Mitral 3.8 (1.5–8.4) 2.0 (1.1–3.3) 9.0 (4.5–16.5) 5.5 (3.7–7.8)
RIND 0.8%/y
Aortic 0.0 (0.0–1.2) –– 0.4 (0.1–2.1) ––
Mitral 0.0 (0.0–1.9) –– 2.0 (0.4–6.4) ––
Stroke 0.8%/y
Aortic 0.0 (0.0–1.2) 0.1 (0.0–0.4) 0.4 (0.1–2.1) 0.4 (0.1–0.9)
Mitral 0.8 (0.1–3.6) 0.7 (0.2–1.6) 3.0 (0.9–8.0) 1.8 (0.9–3.2)
Valve thrombosis 0.8%/y
Aortic 0.0 (0.0–1.2) 0.0 (0.0–0.2) 0.0 (0.0–1.1) 0.1 (0.0–0.4)
Mitral 0.0 (0.0–1.9) 0.0 (0.0–0.4) 1.0 (0.1–4.7) 0.4(0.1–1.3)
Bleeding event 3.5%/y
Aortic 1.4 (0.4–3.7) 1.6 (1.0–2.5) 3.5 (1.7–6.7) 2.1 (1.4–3.1)
Mitral 0.8 (0.1–3.6) 3.0 (1.8–4.6) 6.0 (2.5–12.4) 2.9 (1.7–4.7)
CI, Confidence interval; OPC, Objective Performance Criteria; RIND, reversible ischemic neurologic deficits.was limited documentation on the experience of the St Jude
Medical Silzone prostheses with no concern for excessive
valve-related complications.4-6 These investigators did not
participate in the AVERT trial and found their results supe-
rior to the AVERT results with no identified PPLs.
In 2003, Ionescu and coinvestigators7 reported on the St
Jude Medical Silzone prosthesis experience from the Car-
diff Embolic Risk Factor Study. This significant report
came from a prospective observational study of risk factors
for stroke after valve replacement. These authors compared
the results of 51 patients with Silzone prostheses with 116
patients with St Jude Medical standard prostheses matched
for stroke risk factors. The authors reported comparable re-
sults with AVR, but with MVR, freedom from major throm-
boembolism was 65% for Silzone prostheses and 95% for
standard prostheses at 3 years. Patients in the Silzone group
experienced 6 major strokes and 1 peripheral embolus
within 3 months. There was 1 reoperation for major PPL
in the standard group but none in the Silzone group.
Stalenhoef and coauthors8 reported in 2003 on an experi-
ence with 113 patients receiving Silzone and 101 conven-
tional prostheses in a consecutive series. They identified
very favorable results with no difference in either thrombo-
embolism or paraprosthetic leakage. The authors speculate
that the good results were due to differences in operative
techniques.
The mechanism of defective healing of the sewing cuff to
the annular tissues is not completely understood. It has beenThe Journal of Thoracic and Cpostulated that the Silzone coating inhibits normal fibroblast
growth into the prosthesis sewing cuff.7 The inhibited heal-
ing results in sporadic prosthetic dehiscence with partial and
intermittent lack of tissue ingrowth and endothelization.7
The resultant toxic tissue necrosis can result in thrombus ac-
cumulation and loosening of sutures and paraprosthetic leak-
age.7 The annular necrosis can give the suggestion of
findings compatible with prosthetic valve endocarditis, but
the material is usually culture negative.
Themechanismmay be influential in the alteration of heal-
ing. Ionescu and collaborators7 felt that pledgeted mattress
sutures could cause pressure necrosis from lightened sutures.
There is actually evidence to the contrary. Englberger and
colleagues9 reported for the AVERT study that suture tech-
nique without pledgets was an independent risk factor for
major PPLs. The rate of leaks with pledgets was 1.7% and
5.8%without. The hazard ratiowas 0.3 and 2.5, respectively.
There was no association with valve position.
The important questionofwhether the incidenceof late (>30
days) valve-related complications rates persists with time is
addressed in the summary of the AVERT results presented in
2002 and 2005 (Table 5). The 2002 rates of thromboembolism
and stroke failed to be differentiated statistically.1 In a further
unpublished AVERT analysis in 2005, the stroke rate for
AVR was 0.1%/patient-year for no Silzone and 0.4% for
Silzone.10 The rates for MVR were 0.7%/patient-year and
1.8%/patient-year, respectively.10 The freedom from thrombo-
embolism during the first 5 years was not different (P¼ .54).10ardiovascular Surgery c Volume 137, Number 5 1113
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year for no Silzone and 3.5%/patient-year for Silzone; MVR,
1.5%/patient-year and 7.0%/patient-year, respectively.1 In
2005, the major PPL rates were: 0.4%/patient-year for no
Silzone and 0.6%/patient-year for Silzone for AVR and
0.3%/patient-year and 1.6%/patient-year for MVR, respec-
tively.10 Major PPLs occurred in 17 patients with Silzone
and 6 patients with no Silzone.10 The freedom from major
PPLs for AVR was not different (P ¼ .42) but for MVR
was different (P ¼ .03).10 The overall reoperation for pros-
theses explant at 5 years remained different (P ¼ .001).10
Beyond the 2-year postoperative interval, both the Silzone
and conventional non-Silzone arms were identified as
having 3 major PPLs each.10 In the current study, the overall
freedom from major PPL for AVR, at 7 years, was 94.9%
and for MVR, 97.7%. These freedoms were better for
MVR but slightly worse for AVR compared with the
AVERT rates.
The concept of Objective Performance Criteria (OPC)
was adopted in 1994 by the Food and Drug Administration
of the United States for utilization of approval of valvular
prostheses.11 The 95% confidence interval (32) of the line-
arized occurrence rate (% per patient-year) of any valve-re-
lated complication must be less than double the respective
OPC. The OPCs were determined by meta-analysis for eval-
uation for performance of aortic and mitral prostheses but
not multiple replacements.12 The OPCs are stated in Table
5 with the 2002 and 2005 AVERT rates. In this study, the
calculated linearized occurrence rates for major PPL, major
thromboembolism (strokeþ reversible ischemic neurologic
deficits), and hemorrhage were all within acceptable levels
except major PPL for AVR (95% linearized occurrence
rates 1.34>0.6 OPC 3 2 ¼ 1.2).
In 2006, Grunkemeier and colleagues13 studied the risk
of PPL beyond 5 years to afford advice to the remaining
28,000 patients estimated to be alive with the Silzone pros-
thesis. These authors reported the major PPL rate within 2
years was 1.9%/patient-year14 for Silzone and 0.4%/pa-
tient-year3 for non-Silzone, and event rates beyond 2 years
to 5 years was similar: 0.3%/patient-year in both arms, 3
patients in each arm.13 In the current study, the linearized
occurrence rates for major PPL was 1.3%/patient-year
within 2 years and late after 2 years, 0.4%/patient-year.
Davila-Roman and colleagues14 evaluated all the echocar-
diograms in both arms and reported in 2004. They excluded
the early major PPLs and found no difference in prevalence
or severity of PPLs after 2 years. The identified phy-
siologic regurgitation was found to be hemodynamically
not significant.
There is currently adequate evidence to identify the risk
of major PPL and thromboembolism in the patients who
remain alive with a Silzone prosthesis.13,14 Horstkotte and
Bergemann15 concluded that overall thromboembolic and
hemorrhagic complications are similar for Silzone cuffs1114 The Journal of Thoracic and Cardiovascular Sand conventional cuffs and that the standard antithrombotic
regimes need not be changed. The major PPL rate is now
similar in the Silzone and conventional cuff arms of AVERT
and in the current 7-year study.13,14
The American College of Cardiology/American Heart
Association practice guidelines recommend that asymptom-
atic, uncomplicated patients need only be seen at 1-year
intervals for complete history and thorough physical
examination.16 The follow-up of patients with complications
or potential complications who have had prosthetic heart
valve replacement and do not improve after surgery or later
show deterioration of functional classification should in-
clude appropriate testing, including 2-dimensional and
Doppler echocardiography, and, if necessary, transesopha-
geal echocardiography and cardiac catheterization with
angiography to determine the cause.16 The Canadian
Cardiovascular Consensus on Surgical Management of Val-
vular Heart Disease recommends that Doppler echocardiog-
raphy should be performed between 5 and 30 days after
operation and again between 6 and 12 months after surgery,
after which there is no firm recommendation except that
a study should be performed at the slightest suspicion of dys-
function.17 Dysfunction may be suspected by a reduction in
one functional class from the maximal recovery New York
Heart Association functional class.17 The recommended fol-
low-up interval for echocardiography can be based on the
type of prosthesis and the documented knowledge of poten-
tial dysfunction.17 The follow-up for heterograft bioprosthe-
ses is echocardiography at discharge, 30 days, 6 to 12
months, 5 years, and annually after 7 years for MVR and af-
ter 10 years for AVR or any clinical suspicion of dysfunc-
tion. For mechanical prostheses, echocardiography should
be performed at discharge, 30 days, and 6 to 12 months or
any clinical suspicion of dysfunction.17 The surveillance
of patients with the Silzone prosthesis can now meet recom-
mended standards established for care of patients with
mechanical prostheses. There is no advanced continuing
risk of valve-related complications with the St Jude Medical
Silzone prosthesis after 2 years following implantation.
We extend appreciation to Kevin Shillitto for his work in the
preparation of the manuscript.
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Since the closing interval in November 2005 and statistical
analysis in 2006, there has been an additional late parapros-
thetic leak that led to reoperation at 71 months (5 years,
11 months) following implantation of a Silzone aortic pros-
FIGURE E1. Valve-related reoperation overall and for aortic valve re-
placement (AVR), mitral valve replacement (MVR), and multiple replace-
ments (MR).
FIGURE E2. Paraprosthetic leak reoperation overall and for aortic valve
replacement (AVR), mitral valve replacement (MVR), and multiple replace-
ments (MR).1115.e1 The Journal of Thoracic and Cardiovascular Sthesis. At reoperation, 2 large paraprosthetic leaks were
identified, and further annular decalcification was necessary.
There was no fibrous overgrowth, thrombus, or vegetations.
A small amount of ‘‘rubbery’’ grayish-white to tan-brown
material was identified that was nondiagnostic.
FIGURE E3. Paraprosthetic leak reoperation mortality overall.
FIGURE E4. Overall thromboembolism, minor thromboembolism (TE),
reversible ischemic neurologic deficits, major TE with/without thrombosis
plus major systemic embolism (overall).urgery c May 2009
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A
C
DFIGURE E5. Combined reversible ischemic neurologic deficit (RIND)
and major thromboembolism (major TE) with thrombosis plus major
systemic embolism overall and for aortic valve replacement (AVR), mitral
valve replacement (MVR), and multiple replacements (MR).
FIGURE E6. Combined reversible ischemic neurologic deficit (RIND)
and major thromboembolism (major TE) without thrombosis plus major
systemic embolism overall and for aortic valve replacement (AVR), mitral
valve replacement (MVR), and multiple replacements (MR).The Journal of Thoracic and CardFIGUREE7. Thrombosis overall and for mitral valve replacement (MVR).
FIGURE E8. Antithrombotic hemorrhage overall and for aortic valve re-
placement (AVR), mitral valve replacement (MVR), and multiple replace-
ments (MR).
FIGURE E9. Prosthetic valve endocarditis overall and for aortic valve re-
placement (AVR), mitral valve replacement (MVR), and multiple replace-
ments (MR).iovascular Surgery c Volume 137, Number 5 1115.e2
